Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension
- PMID: 1694932
Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension
Abstract
As hypertension advances, secondary pathophysiologic changes are induced in multiple organs. Consequently, we investigated the pathophysiology of the earliest forms of hypertension--e.g., borderline hypertension. Borderline hypertension is associated with abnormal autonomic control of the circulation; sympathetic drive to the heart, blood vessels, and kidney is increased, cardiac parasympathetic inhibition is decreased, and plasma norepinephrine is increased. The hemodynamic picture is one of increased cardiac output not met by adequate vasodilation. The condition of "hyperkinetic" borderline hypertension is a precursor of more severe hypertension. In due course, a transition from high cardiac output to high vascular resistance occurs, while the enhanced sympathetic tone recedes toward normal values. The mechanism of hemodynamic transition is easily understood: cardiac output decreases due to structural changes and receptor downregulation, whereas ensuing vascular hypertrophy increases vascular resistance. The apparent regression of plasma norepinephrine values is explained in the framework of our hypothesis of the "blood pressure-seeking properties of the central nervous system." Large body mass and overweight are a consistent feature of borderline hypertension. A recent study in Tecumseh, Michigan shows that weight, plasma norepinephrine, a hyperkinetic state, and plasma insulin values are correlated in the general population. The explanation of this interrelationship will greatly advance our understanding of hypertension. From the pathophysiological viewpoint, the paradoxical outcome of clinical trials involving older antihypertensive medication is not surprising. The complexity of pathophysiologic interrelationships and the fact that risk factors for atherosclerosis are increased in hypertension suggest that reduction of blood pressure cannot be expected to ameliorate all consequences of hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Changing role of the autonomic nervous system in human hypertension.J Hypertens Suppl. 1990 Dec;8(7):S59-65. J Hypertens Suppl. 1990. PMID: 2095397 Review.
-
Sympathetic hyperactivity in early stages of hypertension: the Ann Arbor data set.J Cardiovasc Pharmacol. 1988;12 Suppl 3:S121-9. J Cardiovasc Pharmacol. 1988. PMID: 2467097 Review.
-
Abnormalities of autonomic nervous control in borderline hypertension.Schweiz Med Wochenschr. 1976 Dec 4;106(49):1698-705. Schweiz Med Wochenschr. 1976. PMID: 1013692
-
Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure.Scand Cardiovasc J Suppl. 1998;47:23-30. Scand Cardiovasc J Suppl. 1998. PMID: 9540130 Review.
-
Hemodynamics in hypertension at rest and during exercise.J Cardiovasc Pharmacol. 1987;10 Suppl 11:S1-5. J Cardiovasc Pharmacol. 1987. PMID: 2454353 Review.
Cited by
-
Insulin resistance and hypertension--implications for treatment.Postgrad Med J. 1991 Oct;67(792):869-75. doi: 10.1136/pgmj.67.792.869. Postgrad Med J. 1991. PMID: 1758796 Free PMC article. Review. No abstract available.
-
Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic Approaches.Drug Discov Today Dis Models. 2012;9(3):e85-e90. doi: 10.1016/j.ddmod.2012.03.001. Epub 2012 Jun 27. Drug Discov Today Dis Models. 2012. PMID: 23162605 Free PMC article.
-
Hypertensive labeling (reply to Dr. Birkenhäger's editorial).Cardiovasc Drugs Ther. 1993 Aug;7(4):727-9. doi: 10.1007/BF00877827. Cardiovasc Drugs Ther. 1993. PMID: 8241016 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous